Immunotoxin Therapy as an Anticancer Treatment Is a Focus of Current

Multiple Choice

Immunotoxin therapy as an anticancer treatment is a focus of current efforts to develop new anticancer drugs. An alternative strategy, known as radioimmunotherapy, involves the conjugation of a tumor-antigen specific antibody to a radioisotope, rather than to a bacterial toxin. One advantage of radioimmunotherapy over that of immunotoxin therapy is that the radioisotope:

A) Will damage neighboring tumor cells in addition to the cell binding the drug
B) Has a finite half-life and will spontaneously lose activity in the patient
C) Is less likely to cause collateral damage to healthy tissues than the toxin
D) Will not cause inflammation due to recognition by PRRs in innate immune cells, but the toxin will
E) Is unable to bind to Fc receptors on phagocytic cells, so will have increased longevity in patients